ERC017sv2575
UKEi002-A
General
Cell Line |
|
| hPSCreg name | UKEi002-A |
| Cite as: | UKEi002-A (RRID:CVCL_C9HH) |
| Alternative name(s) |
ERC017sv2575
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | |
| Last update | 12th January 2023 |
| User feedback | |
Provider |
|
| Generator | University Medical Center Hamburg-Eppendorf (UKE) |
| Owner | University Medical Center Hamburg-Eppendorf (UKE) |
| Derivation country | Germany |
External Databases |
|
| BioSamples | SAMEA112286195 |
| Cellosaurus | CVCL_C9HH |
| Wikidata | Q123033712 |
General Information |
|
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 15-19 |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | None |
| Is the medical history available upon request? | On request. |
| Is clinical information available? | On request. Healthy heart (MRI, echocardiography). |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Illumina TruSight Cardio Sequencing Kit.
TTN mutation |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA112286196 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Is there other documentation provided to the donor for consenting purposes? | Yes |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a for-profit corporation? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | Double pseudomized |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethik-Kommision der Ärztekammer Hamburg |
| Approval number | PV4798/28.10.2014 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethik-Kommision der Ärztekammer Hamburg |
| Approval number | PV4798/28.10.2014 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | Yes |
| Further constraints on use | Material will be anonymised after 10 years |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
| Source cell origin |
The underside concavity where the arm and the shoulder are joined.
Synonyms
|
| Age of donor (at collection) | 15-19 |
| Collected in | 2015 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Selection criteria for clones | Morphology, growth rate |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzymatically
Accutase
|
| O2 Concentration | 5 % |
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: DMEM/F12: FTDA medium
Main protein source: Albumine Serum concentration: % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Lin28 |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| SSEA-3 |
Yes |
|
| Pluripotency Score | Novelty Score | |
| >20 | 1.7 or higher |
Report
Differentiation Potency
In vitro spontaneous differentiation
In vitro directed differentiation
| Marker | Expressed |
| TNNT2 troponin T2, cardiac type [ Homo sapiens (human) ] |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
mos47,XX,+21[6]/46,XX[9]
Passage number: 21
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Nanostring
|
Login to share your feedback, experiences or results with the research community.